Literature DB >> 26423789

Multifunctional L/N- and L/T-type calcium channel blockers for kidney protection.

Masanori Abe1, Masayoshi Soma1,2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26423789     DOI： 10.1038/hr.2015.106

Source DB:  PubMed          Journal:  Hypertens Res        ISSN： 0916-9636            Impact factor:   3.872


× No keyword cloud information.
  18 in total

Review 1.  The mechanisms underlying altered vascular resistance of glomerular afferent and efferent arterioles in diabetic nephropathy.

Authors:  Shuji Arima; Sadayoshi Ito
Journal:  Nephrol Dial Transplant       Date:  2003-10       Impact factor: 5.992

Review 2.  Haemodialysis-induced hypoglycaemia and glycaemic disarrays.

Authors:  Masanori Abe; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2015-04-07       Impact factor: 28.314

3.  Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis.

Authors:  Natanong Thamcharoen; Paweena Susantitaphong; Supakanya Wongrakpanich; Pakawat Chongsathidkiet; Pakpoom Tantrachoti; Siwadon Pitukweerakul; Yingyos Avihingsanon; Kearkiat Praditpornsilpa; Bertrand L Jaber; Somchai Eiam-Ong
Journal:  Hypertens Res       Date:  2015-07-02       Impact factor: 3.872

4.  Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.

Authors:  Masanori Abe; Kazuyoshi Okada; Noriaki Maruyama; Shiro Matsumoto; Takashi Maruyama; Takayuki Fujita; Koichi Matsumoto; Masayoshi Soma
Journal:  Hypertens Res       Date:  2010-12-02       Impact factor: 3.872

5.  Regulation of glomerular capillary pressure and filtration rate in young Kyoto hypertensive rats.

Authors:  S Azar; M A Johnson; J Scheinman; L Bruno; L Tobian
Journal:  Clin Sci (Lond)       Date:  1979-03       Impact factor: 6.124

Review 6.  Ca2+ channel subtypes and pharmacology in the kidney.

Authors:  Koichi Hayashi; Shu Wakino; Naoki Sugano; Yuri Ozawa; Koichiro Homma; Takao Saruta
Journal:  Circ Res       Date:  2007-02-16       Impact factor: 17.367

7.  Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial.

Authors:  Hiromi Rakugi; Toshio Ogihara; Seiji Umemoto; Masunori Matsuzaki; Hiroaki Matsuoka; Kazuyuki Shimada; Jitsuo Higaki; Sadayoshi Ito; Akira Kamiya; Hiromichi Suzuki; Yasuo Ohashi; Kazuaki Shimamoto; Takao Saruta
Journal:  Hypertens Res       Date:  2013-07-18       Impact factor: 3.872

Review 8.  Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease.

Authors:  B M Brenner; T W Meyer; T H Hostetter
Journal:  N Engl J Med       Date:  1982-09-09       Impact factor: 91.245

9.  Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats.

Authors:  Kai Nagasawa; Keiji Takahashi; Natsumi Matsuura; Miwa Takatsu; Takuya Hattori; Shogo Watanabe; Eri Harada; Kazumi Niinuma; Toyoaki Murohara; Kohzo Nagata
Journal:  Hypertens Res       Date:  2014-09-11       Impact factor: 3.872

10.  An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone.

Authors:  Shokei Kim-Mitsuyama; Hisao Ogawa; Kunihiko Matsui; Tomio Jinnouchi; Hideaki Jinnouchi; Kikuo Arakawa
Journal:  Kidney Int       Date:  2012-10-10       Impact factor: 10.612
View more
  3 in total

Review 1.  Therapeutic Usefulness of a Novel Calcium Channel Blocker Azelnidipine in the Treatment of Hypertension: A Narrative Review.

Authors:  C Venkata S Ram
Journal:  Cardiol Ther       Date:  2022-08-13

2.  Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria.

Authors:  Kiyohiko Takahashi; Akinobu Nakamura; Sho Furusawa; Kei Yokozeki; Hajime Sugawara; Hideyuki Yanagisawa; Kazumasa Akikawa; Hideaki Kikuchi
Journal:  J Clin Transl Endocrinol       Date:  2020-11-25

Review 3.  Calcium channel blocker in patients with chronic kidney disease.

Authors:  Shoko Ohno; Akira Ishii; Motoko Yanagita; Hideki Yokoi
Journal:  Clin Exp Nephrol       Date:  2021-11-08       Impact factor: 2.801
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.